Resolute Advisors’s AbCellera Biologics ABCL Stock Holding History

Resolute Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$452K	Hold	57,526	–	–	0.11%	51
2026 Q1	$201K	Hold	57,526	–	–	0.08%	76
2025 Q4	$197K	Hold	57,526	–	–	0.06%	67
2025 Q3	$289K	Hold	57,526	–	–	0.07%	52
2025 Q2	$197K	Sell	57,526 -4,050	-7%	-$10.1K	0.05%	64
2025 Q1	$137K	Hold	61,576	–	–	0.04%	60
2024 Q4	$180K	Hold	61,576	–	–	0.04%	75
2024 Q3	$160K	Buy	61,576 +4,050	+7%	+$11.2K	0.03%	54
2024 Q2	$170K	Hold	57,526	–	–	0.04%	48
2024 Q1	$261K	Hold	57,526	–	–	0.05%	43
2023 Q4	$328K	Hold	57,526	–	–	0.04%	46
2023 Q3	$265K	Hold	57,526	–	–	0.04%	45
2023 Q2	$372K	Hold	57,526	–	–	0.04%	44
2023 Q1	$434K	Hold	57,526	–	–	0.05%	37
2022 Q4	$583K	Hold	57,526	–	–	0.08%	26
2022 Q3	$569K	Hold	57,526	–	–	0.07%	25
2022 Q2	$613K	Buy	57,526 +14,086	+32%	+$119K	0.06%	27
2022 Q1	$424K	Hold	43,440	–	–	0.02%	45
2021 Q4	$621K	Hold	43,440	–	–	0.02%	37
2021 Q3	$871K	Buy	+43,440	New	+$768K	0.12%	32

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Resolute Advisors's ABCL Position: Q2 2026 in Review

Resolute Advisors held its AbCellera Biologics (ABCL) position steady in Q2 2026 at 57,526 shares worth $452K. The position accounts for 0.11% of the portfolio, ranked #51.

Resolute Advisors first reported a position in ABCL in Q3 2021 and has held it in 20 quarters since. The position peaked at $871K in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Resolute Advisors held 57,526 shares of AbCellera Biologics worth $452K as of Q2 2026.
Resolute Advisors left its AbCellera Biologics share count unchanged in Q2 2026.
AbCellera Biologics made up 0.11% of Resolute Advisors's portfolio in Q2 2026, its #51 holding.
Resolute Advisors first reported a position in AbCellera Biologics in Q3 2021 and has held it in 20 quarters since.
Resolute Advisors's AbCellera Biologics position peaked at $871K in Q3 2021.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Resolute Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.